疑夕2015-05-06 11:19
ASCO2015看点:$Cerulean Pharma(CERU)$ 将公布CRLX101联合贝伐珠单抗治疗肾细胞癌的Ib/IIa期临床结果,3月份时曾宣布达到主要临床终点(50%的患者实现4个月的PFS),详细数据将呈现在ASCO2015。CRLX101是一种纳米粒药物偶联物,加载的药物是喜树碱。(ASCO2015的摘要将在5月13日收盘后公开,想参与...查看全文
$CERULEAN PHARMA INC(CERU)$ 8-K - Current report Filed: 2018-12-10 AccNo: 0001193125-18-346148 Size: 21 MBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$CERULEAN PHARMA INC(CERU)$ 8-K - Current report Filed: 2018-11-29 AccNo: 0001193125-18-338016 Size: 32 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$CERULEAN PHARMA INC(CERU)$ 8-K - Current report Filed: 2018-11-27 AccNo: 0001193125-18-335165 Size: 33 KBItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$CERULEAN PHARMA INC(CERU)$ 10-Q - Quarterly report [Sections 13 or 15(d)] Filed: 2018-11-13 AccNo: 0001564590-18-029135 Size: 4 MB 网页链接
$CERULEAN PHARMA INC(CERU)$ 8-K - Current report Filed: 2018-11-13 AccNo: 0001193125-18-324817 Size: 89 KBItem 2.02: Results of Operations and Financial ConditionItem 9.01: Financial Statements and Exhibits 网页链接
$CERULEAN PHARMA INC(CERU)$ CORRESP [Cover] - Correspondence Filed: 2018-09-20 AccNo: 0001193125-18-278347 Size: 5 KB 网页链接
$CERULEAN PHARMA INC(CERU)$ CORRESP [Cover] - Correspondence Filed: 2018-09-20 AccNo: 0001193125-18-278351 Size: 5 KB 网页链接
$CERULEAN PHARMA INC(CERU)$ CORRESP [Cover] - Correspondence Filed: 2018-09-10 AccNo: 0001193125-18-270115 Size: 23 KB 网页链接
$CERULEAN PHARMA INC(CERU)$ CORRESP [Cover] - Correspondence Filed: 2018-09-20 AccNo: 0001193125-18-278351 Size: 5 KB 网页链接
$CERULEAN PHARMA INC(CERU)$ CORRESP [Cover] - Correspondence Filed: 2018-09-10 AccNo: 0001193125-18-270115 Size: 23 KB 网页链接